Express Pharma

US FDA approves Lilly and Incyte’s Olumiant for treating certain hospitalised patients with COVID-19

Olumiant is the first and only FDA-approved JAK inhibitor for the treatment of COVID-19 in certain hospitalised adults requiring various degrees of oxygen support

0 153

Eli Lilly and Company and Incyte announced recently that the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of COVID-19 in hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever comes first, a company statement said.

The FDA’s approval is supported by results from two randomised, double-blind, placebo-controlled phase-III studies (ACTT-2 and COV-BARRIER, including the COV-BARRIER OS 7 adde